Adipose tissue derived stem cells for regeneration and differentiation into insulin-producing cells

Current Stem Cell Research & Therapy
Song-Cheol KimJiyeon Lee

Abstract

Stem cells are considered an ideal tool for the supply of insulin-producing cells or repairing damaged pancreatic tissues to treat diabetes mellitus, with the possibility of unlimited sources. This cell population includes embryonic, adult bone marrow, pancreatic stem cells, extra pancreatic (such as hepatic cells) and adipose-derived stem cells. Multipotent adipose tissue-derived stem cells (ADSCs) are abundant in the human body, and thus are an ideal donor source for autologous transplantation to generate insulin-producing cells. Moreover these cells are better sources than bone marrow stem cells (BMSCs) for clinical applications, owing to minimal invasive procedures, high proliferation and multi-differentiation potential. Human adipose tissue-derived stem cells (hADSCs) may thus provide an alternative stem cell source, replacing BM-MSCs or embryonic stem cells (ESCs) for future clinical use in diabetes mellitus treatment.

Citations

May 10, 2012·Ageing Research Reviews·Yan PengXiaobing Fu
Oct 24, 2013·Biochemical and Biophysical Research Communications·Ji Sun NamKyung Rae Kim
Mar 8, 2017·Cellular Reprogramming·Farzaneh RamiRasoul Salehi
May 3, 2018·Physiological Reviews·Luc BaeyensHarry Heimberg
Oct 4, 2018·Current Stem Cell Research & Therapy·Junaid KhanShailendra Saraf

❮ Previous
Next ❯

Related Concepts

Related Feeds

Adult Stem Cells

Adult stem cells reside in unique niches that provide vital cues for their survival, self-renewal, and differentiation. They hold great promise for use in tissue repair and regeneration as a novel therapeutic strategies. Here is the latest research.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.